Table of Contents
1. An Overview of Alzheimer's Disease		35. Cholinesterase Inhibitors: Comparison of Dosing Characteristics
2. Normal Aging		36. Cholinesterase Inhibitors: Clinical Use Parameters
3. Dementia		37. Cholinesterase Inhibitors: Clinical Use Parameters (contd)
4. Causes of Dementia		38. Core Symptoms of AD: The ABC's
5. Reversible Dementias		39. Assessment Instrument of Cognition in Alzheimer's Disease
6. Medication-Induced Cognitive Impairment		40. Effect of Donepezil on Cognition: ADAS-Cog*
7. Irreversible Demenias: Causes		41. Long-Term Effects of Donepezil on Cognition: ADAS-Cog*
8. Vascular Dementia:Presentation		42. Long-Term Effects of Donepezil: Recently Published Trials
9. Vascular Dementia:Risk Factors and Prevention		43. Effect of Rivastigmine on Cognition: ADAS-Cog*
10. Alzheimer's Disease:Prevalence in US		44. Galantamine Cognitive Function Over 5 Months vs Placebo
11. Alzheimer's Disease:Economic Burden		45. Galantamine Long-Term Cognitive Function Over 12 Months
12. Alzheimer's Disease: Known Risk Factors		46. Galantamine Long-Term Cognitive Function Over 36 Months
13. Alzheimer's Disease: Suspected Risk Factors		47. Galantamine in the Treatment of Vascular Dementia and Alzheimer's Disease With Cerebrovascular Disease
14. Pathogenesis of Alzheimer's Disease:Macroscopic Changes		48. Galantamine in the Treatment of Vascular Dementia and Alzheimer's Disease With Cerebrovascular Disease: Outcome Measures
15. Pathogenesis of Alzheimer's Disease:Microscopic Changes		49. Galantamine in the Treatment of Vascular Dementia and Alzheimer's Disease With Cerebrovascular Disease: Results
16. Pathogenesis of Alzheimer's Disease:Protein Abnormalities		50. Newer Therapies:Glutamate Hypothesis of Cognitive Deficit
17. Pathogenesis of Alzheimer's Disease Neurotransmitter/Oxidative Deficits		51. Memantine: Mechanism of Action
18. Pathogenesis of Alzheimer's Disease: An Overview		52. Memantine: Pharmacokinetics
19. Alzheimer's Disease:Diagnosis		53. Memantine: Pharmacokinetics
20. Probable Alzheimer' s Disease:NINCDS/ADRDA* Criteria		54. Memantine: Development History
21. Diagnosis: The Clinical Exam		55. Memantine: Pivotal Published Clinical Trials
22. Diagnosis: Screening Tests		56. Memantine Clinical Trial Summary
23. Diagnosis: Assessment Tests for Clinical Trials		57. Memantine: Safety and Tolerability
24. Evaluation:Neuroimaging Techniques		58. Neuroinflammation:What Do We Know?
25. Evaluation:Laboratory Workup		59. Neuroinflammation:Rofecoxib and Naproxen Trial
26. Alzheimer's Disease:Typical Course		60. Neuropathological Processes:Estrogen Trials
27. Alzheimer's Disease:Treatment Strategy		61. What about Statins and AD?
28. Pharmacologic management: Goals of Therapy		62. Neuropathological Processes:Vitamin E Clinical Trial
29. Role of Neurotransmitters: Cholinergic Hypothesis		63. Neuropathological Processes:Ginkgo biloba
30. Cholinergic Changes in AD		64. Practice Recommendations: AAN* Guidelines for Pharmacologic Treatment of AD
31. Role of Nicotinic Receptors in AD		65. Conclusions
32. Cholinesterase Inhibitors for AD: Approved in the US		66. Alzheimer's Disease:Pharmacist Interventions
33. Cholinesterase Inhibitors:Pharmacology		67. Selected Internet Resources
34. Cholinesterase Inhibitors: Comparison of Pharmacokinetics		References